Stem cell product potency is measured with laboratory assays that show a batch’s relevant biological activity. Depending on the product, this may involve a functional test, a justified surrogate measurement, or several complementary assays. Cell count and viability are useful quality checks, but they do not establish potency for every product. There is no universal stem cell potency test or passing score.Potency tests cellular and gene therapy products
Two Meanings of Potency
In basic biology, developmental potency means the range of cell types a stem cell can become. Pluripotent cells can form all adult-body cell types; adult stem cells generally produce the specialized cells of their own tissue. Researchers assess this potential through evidence of differentiation, rather than a treatment’s cell count.Stc basics

For a manufactured treatment, product potency concerns biological activity relevant to its intended effect. This is the meaning used in batch-release testing. A cell’s ability to become several tissue types does not, by itself, establish the potency of a product intended to modify an immune response.Potency tests cellular and gene therapy products
What the Main Tests Measure
| Measurement | What it tells you | Main limitation |
|---|---|---|
| Cell count | The number of cells in a sample or dose | Does not automatically show biological activity |
| Viability | The proportion of cells judged alive by the specified method | A living cell is not necessarily performing the intended function |
| Identity markers | Whether cells have characteristics expected for that population | Identity alone does not establish the proposed therapeutic activity |
| Functional assay | A defined biological response under controlled conditions | The response must be relevant to the product’s intended activity |
| Surrogate assay | An indirect attribute linked to biological activity | Requires evidence supporting that product-specific link |
These measurements answer different questions. FDA’s potency guidance allows biological assays, supported analytical assays, and assay matrices; it does not require the same test combination for every cell product.Potency tests cellular and gene therapy products
How Labs Build a Potency Test
Choose the Relevant Activity
The starting point is what the product is intended to do. A test of blood-forming progenitor growth answers a different question from a test of immune-cell suppression. Manufacturers use product characterization and development data to identify measurable activities related to the proposed mechanism.Potency tests cellular and gene therapy products
Measure Function or a Supported Surrogate
A biological assay measures activity in a living system, such as cultured cells. A non-biological analytical assay may instead measure a molecular, biochemical, or immunochemical attribute. It can serve as a potency surrogate when evidence links that measurement to the relevant biological activity; a marker or protein amount does not qualify merely because it is easy to measure.Potency tests cellular and gene therapy products
When one assay is insufficient, an assay matrix combines complementary measurements. FDA describes matrices made from biological assays, biological plus analytical assays, or analytical assays alone when appropriately supported. A separate functional bioassay is therefore not a universal requirement for every released batch.Potency tests cellular and gene therapy products
Set Controls and Acceptance Criteria
For licensed products within this FDA framework, release potency testing needs quantitative data, suitable controls or reference materials, and predefined acceptance or rejection criteria. The assay must be sufficiently reliable for its purpose. FDA also recommends showing that a surrogate method can distinguish active product from inactive or degraded material.Potency tests cellular and gene therapy products
A result may be expressed as activity units, a concentration, a percentage response, or another product-specific readout. The number is meaningful only alongside the method and its acceptance criteria. Potency measurements also support stability and manufacturing-comparability studies; an early development result is not a substitute for the applicable release testing of a later batch.Potency tests cellular and gene therapy products
A Cord-Blood Label Example
The U.S. label for HEMACORD, a cord-blood hematopoietic progenitor cell product, states that cord-blood potency is determined by total nucleated cell numbers, CD34-positive cell numbers, and cell viability. This is a product-specific example, not a rule for all stem cell preparations.DrugInfo.cfm?setid=bd9a5180 1773 11e0 980a 0002a5d5c51b
| HEMACORD label measure | Figure | How to interpret it |
|---|---|---|
| Minimum total nucleated cells | 500 million per unit | At cryopreservation, not a guaranteed post-thaw count |
| Minimum viable CD34-positive cells | 1.25 million per unit | A subset within the unit, not an additional 1.25 million cells to add to the total |
| Recommended minimum dose | 25 million nucleated cells per kilogram | At cryopreservation; multiple units may be required |
The figures above come from the label’s dosage and description sections. The actual unit’s cell content is documented on its container label and accompanying records. The indication is unrelated-donor transplantation with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in specified disorders affecting the blood-forming system.DrugInfo.cfm?setid=bd9a5180 1773 11e0 980a 0002a5d5c51b
These numbers are not a dosing guide for a private clinic’s MSC infusion. HEMACORD transplantation carries serious risks, including fatal infusion reactions, graft-versus-host disease, engraftment syndrome, graft failure, donor-origin malignancy, and transmission of infection. Meeting a labeled cell count does not eliminate those risks.DrugInfo.cfm?setid=bd9a5180 1773 11e0 980a 0002a5d5c51b
How MSC Potency Differs
For mesenchymal stromal cells (MSCs), a familiar marker panel is not a complete potency result. The 2006 International Society for Cellular Therapy criteria describe cultured human MSCs through plastic adherence, specified surface markers, and differentiation into bone, fat, and cartilage in vitro. These identify a laboratory cell population; they are not a universal efficacy or release-potency standard.16923606
A product intended to affect immune responses needs evidence relevant to that activity. Differentiation into bone or cartilage alone would not establish immune-modulating potency. A functional immune-response assay or a justified surrogate may contribute to the potency strategy, with a matrix used when one measurement is insufficient.Potency tests cellular and gene therapy products
Approval is also product- and indication-specific. On December 18, 2024, FDA approved Ryoncil, a donor bone-marrow-derived MSC therapy, for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. That approval does not establish the efficacy of other MSC preparations or other uses.Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
How to Read a Potency Claim
Consider a treatment quote that lists only a cell total and a viability percentage. Those two numbers do not tell you which biological activity was tested. When assessing a stem cell clinic’s documentation, ask for the product name, the lot identifier, the assay name, and an explanation of how the readout relates to the intended activity.
Work Through the HEMACORD Example
Start with the time point: the label’s minimum cell figures apply at cryopreservation. Do not rewrite them as the number of viable cells infused after thawing. Next, distinguish total nucleated cells from viable CD34-positive cells; they are not interchangeable measurements. Finally, separate the per-unit minimum from the weight-based dose recommendation. A unit meeting its content specification does not, by itself, establish that it supplies an individual’s required dose.DrugInfo.cfm?setid=bd9a5180 1773 11e0 980a 0002a5d5c51b
This label-reading example does not assess an individual patient’s treatment. For another product, use its own specifications rather than carrying over HEMACORD’s numbers.
Ask for the Missing Context
- What is the cell source, and is the product autologous or donor-derived?
- What activity does the potency assay measure, and is it a direct bioassay or a supported surrogate?
- Does the result apply to the lot proposed for treatment, and what were the acceptance criteria?
- When was the sample tested relative to freezing, thawing, storage, and administration?
- Which clinical evidence supports the exact product, condition, and administration route?
- What were the study population, sample size, comparator, endpoints, follow-up, and adverse events?
If a report shows only identity markers or viability, ask for the missing potency evidence rather than assuming the product has passed or failed. A commercial summary may omit information contained in the manufacturer’s testing records.
What Potency Testing Cannot Prove
A potency result is not a promise that treatment will help an individual. It cannot replace clinical evidence on benefits and harms. A laboratory response or animal result does not, by itself, establish benefit in people, and evidence from a different cell product, disease, dose, or administration route should not be treated as interchangeable.Potency tests cellular and gene therapy products
Check regulatory status separately from the assay result. An approved product, an experimental intervention in a study, and a private clinic service are different categories. A study registration or a regulatory filing should not be read as proof that a treatment works. Ask for the actual approval and its indication, or for a clear explanation of the investigational or service framework.
The Bottom Line
Stem cell potency is measured through product-specific evidence of biological activity, not one universal percentage or cell count. Look for a relevant assay or supported assay matrix, lot-specific results, and clear acceptance criteria. HEMACORD’s 500-million-cell unit minimum illustrates why the product, units, and measurement time matter; it is not a potency target for other therapies.DrugInfo.cfm?setid=bd9a5180 1773 11e0 980a 0002a5d5c51b
This article provides general information, not medical advice. A qualified treating physician should interpret product testing alongside the diagnosis, clinical evidence, risks, and alternatives.
Preparing questions about a treatment quote? Ask which product documents are available before making a decision.
References
- FDA. Potency Tests for Cellular and Gene Therapy Products. Final guidance, January 2011. Product-specific assays, surrogate measurements, assay matrices, and release-testing principles.
- NIH. Stem Cell Basics. Developmental potential and stem cell differentiation.
- DailyMed. HEMACORD prescribing information. Sections 1, 2.1, 3, 5, and 11: indication, dose, unit content, warnings, and potency description. Label revised May 2015.
- Dominici M et al. Minimal criteria for defining multipotent mesenchymal stromal cells. ISCT position statement, Cytotherapy, 2006. PubMed bibliographic record; laboratory identity criteria, not evidence of treatment benefit.
- FDA. Approval of the first mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease. December 18, 2024. Ryoncil’s specific approved population and indication.




